Cdc traveler-based genomic surveillance program to expand to two new us international airports in miami and chicago

The tgs program, a leading example of biosecurity infrastructure, operates at a total of nine us locations and leverages voluntary nasal swabs as well as wastewater sampling from international travelers to detect more than 30 pathogens. boston, march 12, 2024 /prnewswire/ -- ginkgo bioworks (nyse: dna), which is building the leading platform for cell programming and biosecurity, the centers for disease control and prevention (cdc), and xprescheck, by xwell, inc. (nasdaq: xwel), a leader in the delivery of onsite pathogen screening, today announced they are expanding the cdc's traveler-based genomic surveillance program (tgs) to new collection locations at us international airports in miami (mia) and chicago (ord).
DNA Ratings Summary
DNA Quant Ranking